NewG Lab Pharma Develops Diabetes Combination Drug... "Synergy Through Direct Distribution"

[Asia Economy Reporter Hyunseok Yoo] NewG Lab Pharma's subsidiary, NewG Lab Therapeutics, has succeeded in developing a diabetes combination therapy formulation that improves medication convenience based on its proprietary formulation technology.

NewG Lab Therapeutics announced on the 7th that it has submitted an Investigational New Drug (IND) application for the Phase 1 clinical trial of ‘NGL-101,’ a diabetes combination therapy containing the active ingredients ‘Dapagliflozin’ and ‘Sitagliptin,’ to the Ministry of Food and Drug Safety (MFDS).

This combination drug has clinical evidence supporting co-administration, allowing approval with only a Phase 1 clinical trial. In particular, the diabetes combination therapy ‘NGL-101’ will be manufactured by ‘Arije Yak’ and directly distributed by its parent company NewG Lab Pharma, making the synergy between affiliated companies visible. NewG Lab Pharma has already obtained a pharmaceutical wholesale and retail license for drug distribution, and it is expected to realize full-scale sales and profits through this.

‘Dapagliflozin’ is an ‘SGLT2’ protein inhibitor and is the diabetes treatment drug ‘Forxiga’ sold by AstraZeneca (AZ). ‘Sitagliptin’ refers to the ‘DPP-4’ protein inhibitor ‘Januvia’ sold by MSD. NGL-101 is a combination drug that enhances the therapeutic effect of diabetes by prescribing these two drugs in a single pill.

A representative of NewG Lab Therapeutics said, “The domestic diabetes treatment market is currently dominated by Forxiga and Januvia, and these two drugs are co-prescribed to many patients,” adding, “We are preparing to launch ‘NGL-101’ in line with the expiration of Januvia’s patent in September next year.”

This year, NewG Lab Therapeutics is preparing to launch a differentiated generic drug with improved convenience for urological disease treatment, including one bioequivalence study, as well as new formulation over-the-counter drugs for pain and rhinitis treatment, in addition to the diabetes combination therapy. Going forward, NewG Lab Therapeutics plans to continuously release two to three or more new products annually.